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Background. Vancomycin-resistant enterococci (VRE) have triggered multiple outbreaks. However, VRE of
genotype vanC appear not to be associated with outbreaks. The goal of this study was to estimate the risk of
bloodstream infections in patients colonized with VRE of genotype vanC who received care from a bone marrow
transplant unit for patients with leukemia, where only standard precautions were implemented for VRE of genotype
vanC during the last 9 years.
Methods. Since 2000, all patients in the bone marrow transplant unit underwent routine VRE rectal screening,
data were prospectively entered in a database, and isolates were molecularly characterized. Infection control policy
required contact isolation for patients infected with VRE of genotype vanA or vanB but only standard precautions
for patients infected with VRE of genotype vanC.
Results. From January 2000 to July 2008, 290 isolates of VRE of genotype vanC obtained from 273 different
patients were identified, with an incidence of 25–43 isolates/year. Of 290 isolates, 285 (98%) were identified in
rectal screening swabs, 5 were from other body sites, and none required specific treatment. During the entire study
period, only 1 case of bloodstream infection was detected, reflecting an incidence of 1 (0.4%) of the 273 patients,
or !0.2 cases per 1000 patient-days. No outbreaks were recorded.
Conclusions. These data provide strong evidence that carriers of VRE of genotype vanC do not require contact
isolation, thereby saving resources and potentially improving patient care. The genotype should be routinely
determined in areas with a high prevalence of VRE of genotype vanC.
Vancomycin-resistant enterococci (VRE) were first de-
scribed in Europe in 1988 [1, 2] and have rapidly spread
worldwide ever since, including to the United States
[3]. The percentage of nosocomial infections caused by
VRE increased 120-fold (from 0.3% to 7.9%) between
1989 and 1993 in the United States [4]. This increase
was mainly caused by an increase in VRE infections
among intensive care unit (ICU) patients, although the
same trend could also be observed in non-ICU patients
[5]. The emergence of VRE has led to multiple epi-
demics and outbreaks in several hospital settings [6–
10]. Infections with these pathogens have been asso-
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ciated with poor outcomes and vancomycin resistance
has been shown to be an independent predictor of death
in enterococcal bacteremia [11].
There are 6 recognized phenotypes of vancomycin
resistance: VanA, VanB, VanC, VanD, VanE, and VanG
[12]. Five of these types correspond to acquired resis-
tance (VanA, VanB, VanD, VanE, and VanG); one
type—VanC—is an intrinsic property of Enterococcus
gallinarum and Enterococcus casseliflavus. The VanC
phenotype is characterized by intrinsic low-level resis-
tance to vancomycin and susceptibility to teicoplanin
[13, 14].
Human enterococcal infections are mainly caused by
2 species, Enterococcus faecalis and Enterococcus faecium,
which express the VanA or VanB phenotype [15], and
most published outbreaks of VRE have been restricted
to these 2 classes of vancomycin resistance. The resis-
tance genes are harbored on plasmids for the VanA and
VanB phenotypes, whereas the VanC phenotype is an
intrinsic feature, which is not found on plasmids or
transposons but is encoded chromosomally. Other spe-
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Figure 1. Incidence of vancomycin-resistant enterococci (VRE) of ge-
notypes vanA, vanB, and vanC identified per 100 patients.
Figure 2. Detection of vancomycin-resistant enterococci of genotype vanC in different specimens.
cies, like E. gallinarum and E. casseliflavus, which exhibit the
VanC phenotype, are less common, and outbreaks have been
reported rarely [16, 17]. In contrast to VRE of genotypes vanA
and vanB, VRE of genotype vanC (hereafter, referred to as “VRE
vanC”) are associated with a low risk of mortality [18].
The Centers for Disease Control and Prevention recommend
contact isolation precautions for patients colonized or infected
with VRE, without mentioning specific precautions for enter-
ococci expressing the vanC genotype [19]. However, many in-
stitutions in the Netherlands and Switzerland do not follow
this recommendation, because this intrinsic chromosomal re-
sistance is not found on plasmids and transposons that might
spread to other bacteria. VRE vanC are common in Europe
but are rare in the United States [11]. There are insufficient
data to support the practice of nonisolation of patients colo-
nized or infected with VRE vanC.
This study has 2 aims: first, to estimate the risk of invasive
infections for patients colonized with VRE vanC and, second,
to provide clinical data on the level of transmissibility.
METHODS
Setting. The University Hospital of Basel is an 855-bed ter-
tiary care center in Basel, Switzerland. The bone marrow trans-
plant unit performs 80–100 stem cell transplantations per year,
with predominantly allogeneic transplantations (42–77 per year).
Patients and data collection. Rectal swabs to detect VRE
were routinely performed during each hospitalization. The da-
tabase of all consecutive VRE vanC isolates from patients on
the bone marrow transplant unit in the University Hospital of
Basel was studied from January 2000 to July 2008. Information
was obtained from the computerized database of the clinical
microbiology unit, and patients whose cultures from any body
site yielded VRE vanC were identified.
An infectious diseases specialist then reviewed the medical
records of these patients and collected data regarding patient
demographic characteristics, underlying diseases or condition,
clinical manifestations at the time of detection of VRE vanC
from a normally sterile body fluid, prior antibiotic use, anti-
biotic therapy received, bacteremia with any kind of micro-
organism, and clinical outcome. We included 1 positive rectal
swab specimen per patient per year. The study was approved
by the local ethics committee as part of the quality assurance
program.
Definitions. Invasive infections were defined by detection
of VRE vanC from a normally sterile body fluid in addition to
clinical assessment. Clinically significant bacteremia due to VRE
vanC was defined by isolation of VRE vanC in 1 blood culture.
Species identification and genotyping. Rectal swab speci-
mens were screened for VRE by use of a selective enrichment
broth (BBL Enterococcosel Broth; Becton Dickinson) supple-
mented with vancomycin (6 mg/L). Subcultures were per-
formed on BBL Vancomycin Screen Agar containing 6 mg/L
vancomycin (Becton Dickinson) and blood agar. Identification
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Table 1. Characteristics of Patients with Vancomycin-Resistant
Enterococci of Genotype vanC (VRE vanC) Identified in Rectal
Screening Swab Specimens
Characteristic
Patients with VRE
vanC in rectal swab
specimen
( )np 260
Age, mean years 45.8
Sex
Female 117 (45)
Male 143 (55)
Hospital stay, mean days 39.1
Autologous stem cell transplantation 57 (21.9)
Allogeneic stem cell transplantation 123 (47.3)
Chemotherapy 88 (33.8)
No antibiotic therapy 31 (11.9)
Antibiotic therapy 229 (88.1)
Amikacin 100 (38.5)
Vancomycin 51 (19.6)
Carbapenem 96 (36.9)
Cefepim 140 (53.8)
Piperacillin-tazobactam 143 (55.0)
Other 106 (40.8)
Blood stream infection
1 Episode 61 (23.5)
2 Episodes 12 (4.6)
3 Episodes 4 (1.5)
None 183 (70.4)
Outcome
Discharge 223 (85.8)
Transfer to another hospital 9 (3.4)
Death 28 (10.8)
of glycopeptide resistance genotypes (VanA, VanB, VanC1, and
VanC2/3) and enterococcal species of VRE was molecularly
confirmed by use of polymerase chain reaction (PCR) and the
DNA strip GenoType Enterococcus assay (Hain Lifescience).
Molecular typing of 9 consecutive exemplary strains of VRE
vanC selected at random was performed by pulsed-field gel
electrophoresis (PFGE) [20]. In brief, the DNA restriction frag-
ments were separated after SmaI digestion by PFGE, and den-
drograms were drawn using the computer software GelCompar,
version 4.5 (Applied Maths).
RESULTS
From January 2000 through July 2008, 296 isolates of VRE
from all body sites were obtained from 273 different patients
who received care on the bone marrow transplant unit of the
University Hospital of Basel. Resistance genotype identification
through PCR revealed the VanC genotype in 290 (98%) of the
296 isolates. This accounts for an incidence of 25–43 VRE vanC
isolates per year, corresponding to 29–43 patients per year. The
incidence of VRE of genotypes vanA and vanB was very low,
calculated as cases per year (Figure 1).
Of the 290 VRE vanC isolates, 285 (98%) originated from
rectal screening swab specimens, and only 5 isolates were found
in other specimens, possibly suggesting invasive infection (Figure
2). The majority of the 285 rectal swabs with detection of VRE
vanC (173 [60.7%]) were performed in the first 3 days after
admission. A total of 193 (67.7%) of the 285 patients with rectal
swab specimens positive for VRE vanC tested positive at ad-
mission. Of the remaining 92 patients, 73 had positive specimens
after repeated sampling. Among the 92 patients with positive
rectal swabs after the first week of admission, 35 (12.3% of 285
patients) tested positive in the second week, 18 (6.3%) in the
third week, and 39 (13.7%) after 3 weeks of hospitalization.
Medical chart review could be completed for 260 of the 273
different patients. A total of 13 patients were lost to further
follow-up.
The baseline characteristics of the 260 patients with detection
of VRE vanC are summarized in Table 1. The mean age of the
patients with detection of VRE vanC was 45.8 years, and there
was a slight predominance of the male sex (55%). A total of
69.2% underwent stem cell transplantation, mainly allogeneic.
The vast majority of patients (88.1%) received broad-spectrum
antibiotic treatment during their hospital stay in accordance
with the local guidelines of the institutions with either cefepime,
piperacillin-tazobactam, or meropenem. Vancomycin was only
given to 19.6%, mainly to patients with suspected catheter-
related infection. Blood-stream infection with any microorgan-
ism was documented in 29.6% of all patients. The most com-
monly isolated pathogens were coagulase-negative staphylo-
cocci (38.4% of all 99 bloodstream isolates) and Escherichia coli
(18.2% of all 99 bloodstream isolates). Acute myeloid leukemia
and acute lymphoblastic leukemia were the underlying he-
matological illnesses encountered most frequently, occurring in
48% and 13% of patients, respectively.
The 5 specimens detected from body sites other than the
rectum originated from 4 different patients (Table 2). After full
medical chart review by 2 board-certified infectious diseases
specialists, the detection of VRE vanC in 3 patients was inter-
preted as colonization. The fourth patient, who had detectable
VRE vanC in blood cultures and in culture of a superficial
wound swab specimen, showed a favorable outcome. Over-
all, only 1 case of bloodstream infection was detected, reflect-
ing an incidence of 1 (0.4%) of 273 patients, or !0.2 cases per
1000 patient-days.
Comparison of the results obtained by PFGE of 9 represen-
tative strains of VRE vanC detected during the entire study
period revealed no evidence of identity. No evidence of an
outbreak was recorded during the entire study period.
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Table 2. Patients with Detection of Vancomycin-Resistant Enterococci of Genotype vanC (VRE vanC) in Spec-
imens from Various Body Sites
Patient
Age,
years Sex
VRE vanC in rectal
swab specimen
VRE vanC in
clinical specimen Clinical diagnosis Outcome
1 51 M Yes Deep wound swab Colonization Cured
2 53 M Yes Blood and superficial
wound swab
Bloodstream infection Cured
3 63 F No Respiratory tract specimen Colonization Deceased
4 69 F Yes Superficial wound swab Colonization Cured
DISCUSSION
Throughout the study period, 296 isolates of VRE were detected
from all body sites tested. The vanC genotype was detected in
290 isolates and thus represented the vast majority of all VRE
isolates. This finding represents an incidence of 25–43 VRE
vanC isolates per year. The predominance of the vanC genotype
has also been reported in other European countries [21]. In
contrast, the vanA and vanB genotypes account for ∼67% and
25% of all VRE isolates in the United States, respectively [22].
This difference may be because avoparcin—a glycopeptide—
was used in large amounts in the European food industry un-
til it was banned in April 1997 by the European Commission.
This was not the case in the United States. In countries using
avoparcin, vancomycin-resistant enterococci were commonly
found in the commensal flora of food animals, in meat from
these animals, and in the commensal flora of healthy humans,
despite very limited use of vancomycin in hospitals [23].
Of the 290 VRE vanC isolates, 285 (98%) originated from
rectal swab specimens, accounting for an incidence that ranged
from 21 to 46 VRE vanC isolates per 100 patients throughout
the entire study period. Gordts et al [24] described a prevalence
of 3.5% for VRE colonization of the intestinal tract in hospi-
talized patients, with the vast majority of VRE of genotype
vanA. The study included all patients admitted to the hospital
and did not focus on a bone marrow transplant unit. The
duration of stay in a hematology department was, however,
identified as a risk factor for VRE colonization.
During the entire study period from January 2000 to July
2008, only 1 case of bloodstream infection due to VRE vanC
was detected among colonized patients. This reflects an inci-
dence of 1 (0.4%) of 273 patients, or !0.2 cases per 1000
patient-days. Our data therefore demonstrate an extremely low
risk for invasive infection caused by VRE vanC in colonized
patients on a hematology transplant unit. To our knowledge,
this is the first study to assess the risk of invasive infection in
patients on a hematology transplant unit who are colonized
with VRE vanC.
The patient with bloodstream infection due to VRE vanC
had a favorable clinical outcome. However, VRE vanC have
been reported to cause serious infections, including endocar-
ditis [25, 26], meningitis [27], liver abscess [28], and primary
bacteremia [25].
Reid et al [25] reported 20 cases of VRE vanC bloodstream
infection with serious outcomes: 4 patients died within 6 days
after admission to the hospital, and another 4 patients died 1–
2 months after the episode of bacteremia. The authors therefore
concluded that E. gallinarum and E. casseliflavus may cause
serious invasive disease. However, all the patients described had
serious underlying diseases, so it was difficult to attribute their
mortality directly to infection with VRE vanC. Furthermore, a
large proportion (45%) of the described patients had poly-
microbial bacteremia in which aerobic gram-negative bacilli
were the predominant blood coisolates recovered, which fur-
ther complicates the analysis of the relationship between mor-
tality and the detection of VRE vanC in blood cultures.
A low risk of mortality associated with bacteremia due to E.
casseliflavus and E. gallinarum was postulated by Choi et al [18]
in their analysis of 56 cases of bacteremia due to VRE vanC.
However, the majority of the described patients (75%) had
biliary disease as an underlying condition, and only 1 patient
had an underlying hematological illness. This study supports
our finding of a favorable clinical outcome of VRE vanC bac-
teremia in a limited manner, because of the different patient
characteristics.
No differences in severity of illness or mortality between
different enterococcal species were found by De Perio et al [29],
who compared the outcomes of 33 patients with non–E. faecalis
and non–E. faecium enterococcal bacteremia with those of pa-
tients with E. faecalis bacteremia. In Japan, of 9 patients with
VRE vanC bacteremia, 4 died; however, the authors of the study
did not specify whether death was directly attributed to infec-
tion with VRE vanC [30].
All VRE vanC strains detected during the entire study period
revealed no evidence of identity by PFGE analysis. The majority
of rectal swabs (60.7%) that had detection of VRE vanC were
performed within the first 3 days after admission, whereas 92
rectal swab specimens tested positive after the first week of
hospitalization. For 73 of the 92 patients, the initial rectal swab
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specimen obtained at admission tested negative for VRE, sug-
gesting nosocomial transmission. The vast majority of patients
(88.1%), however, received broad-spectrum b-lactam treatment
during their hospital stay, selecting for enterococci in the gas-
trointestinal flora and, thus, facilitating detection of VRE. [31].
In addition, D’Agata et al [32] found antibiotic exposure to be
significantly associated with higher VRE density in stool; the
sensitivity of rectal swab specimen cultures was only 58%, rang-
ing from 100% at VRE densities of 7.5 log10 colony forming
units (cfu) per gram of stool to 0% at densities of 4.5 log10
cfu per gram of stool. Therefore, it is conceivable that the
delayed detection of VRE relates to the sensitivity of the culture
method, rather than being evidence of nosocomial transmis-
sion. Stable incidence rates could be documented, and no ad-
ditional outbreaks were recorded by our continuous surveil-
lance system during the observed study period. We therefore
concluded that no transmission of any clinical relevance had
taken place, although contact isolation precautions for patients
colonized or infected with VRE, which are recommended by
the Centers for Disease Control and Prevention, were not im-
plemented. However, our data were collected in a highly spe-
cialized bone marrow transplant unit with a very high standard
of routine infection control strategies. This may limit the ap-
plication of our results to normal hospital wards.
Only 2 outbreaks due to VRE vanC have been reported so
far. The first outbreak was reported to involve 9 otherwise
healthy patients who underwent total knee arthroplasty in a
single orthopedic unit. They consecutively developed prosthe-
sis-associated infection caused by a single strain of E. gallinarum
nearly 4 months later. To find a source of exposure, environ-
mental cultures and select personnel cultures were performed;
results of these cultures, however, were negative. In summary,
no source was implicated, and no major breaches in infection
control could be identified [16].
The second outbreak was identified because of an unusual
increase in the number of infections caused by vancomycin-
resistant E. gallinarum in a Colombian tertiary care teaching
hospital. Eleven cases were identified, and E. gallinarum could
be isolated in cultures of blood from 4 patients, surgical se-
cretions from 4 patients, paranasal sinus secretion from 1 pa-
tient, a lung abscess from 1 patient, and urine from 1 patient.
The mortality of the patients infected with E. gallinarum was
higher than that of control subjects (18% vs 9.7%), although
this difference was not statistically significant. The authors
therefore concluded that VRE vanC are capable of spreading
in a hospital environment and can cause a substantial number
of nosocomial infections. Furthermore, they recommended the
implementation of infection control measures if an outbreak
occurs [17].
Several limitations of this study should be discussed. Patients
are mainly kept in single or 2-bed rooms. Less than 10% of all
hospital beds are in 3- or 4-bed rooms. In addition, we cannot
rule out special precautions for patients with hematological
malignancies. However, these precautions were never applied
to these patients, although they can be ordered by the treating
physicians, and such precautions were not documented in the
charts.
Despite these 2 reports of outbreaks, we believe that our find-
ings clearly demonstrate no need for contact isolation of patients
colonized or infected with VRE vanC. We therefore propose that
the Centers for Disease Control and Prevention guidelines [19]
should be adapted for VRE vanC, to avoid unnecessary isolation
days. Furthermore, we could demonstrate an extremely low risk
of invasive infection in colonized patients with underlying he-
matological disorders and immunosuppression.
These data provide strong evidence that carriers of VRE vanC
do not require contact isolation, thereby saving resources and
potentially improving patient care. The genotype of VRE should
be routinely determined in areas with a high prevalence of VRE
vanC.
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